Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease

Victoria Nankivell, Achini K. Vidanapathirana, Ayla Hoogendoorn, Joanne T. M. Tan, Johan Verjans, Peter J. Psaltis, Mark R. Hutchinson, Brant C. Gibson, Yiqing Lu, Ewa M. Goldys, Gang Zheng, Christina A. BursillCardiovascular 2024 · DOI

TL;DR

This review explores the exciting potential of multifunctional nanoparticles (NPs) to revolutionize the diagnosis and treatment of atherosclerotic cardiovascular disease (CVD). By specifically targeting macrophages, key players in plaque development, these NPs offer a dual approach to improve plaque detection and deliver targeted therapies, aiming for better outcomes with fewer side effects.

What Problem Does This Paper Address?

Atherosclerotic cardiovascular disease (CVD) remains a leading cause of death and disability, despite advances in treatment. A major challenge is the accurate and early detection of unstable plaques, which are prone to rupture and cause heart attacks or strokes. Current imaging techniques often lack the sensitivity and specificity to identify these high-risk plaques at a molecular or cellular level. Furthermore, existing treatments, like statins, are often broad-acting and don't fully address the complex biological mechanisms driving plaque progression, leaving a significant portion of patients with residual risk. Macrophages, a type of immune cell, are central to the development and instability of atherosclerotic plaques, making them an ideal target for both diagnostic and therapeutic interventions.

Methods

This paper is a review, so it doesn't present new experimental methods. Instead, it synthesizes existing research on nanoparticle (NP) technologies for atherosclerosis. The authors discuss various NP designs and their applications, categorizing them by:

  • Nanomaterial Type: Inorganic (e.g., gold, iron oxide), carbon-based (e.g., carbon nanotubes), and lipid-based (e.g., liposomes, HDL-like NPs).
  • Targeting Strategies: How NPs are designed to specifically bind to macrophages or their associated markers (e.g., CD47, CCR2, scavenger receptors).
  • Imaging Modalities: How NPs incorporate imaging agents (e.g., fluorescent dyes, MRI contrast agents) for visualization.
  • Therapeutic Components: How NPs deliver drugs or genetic material (e.g., siRNA, statins, photosensitizers) to modulate macrophage function.
  • Macrophage Functions Targeted: This includes inhibiting inflammation, reducing lipoprotein oxidation, promoting cholesterol efflux, restoring defective efferocytosis, and inducing macrophage ablation.

The review also highlights the concept of "theranostics" – NPs that combine diagnostic and therapeutic capabilities.

Datasets

Not discussed in the paper. This is a review article summarizing existing research, not a study that collected or analyzed new datasets.

Key Insights and Ideas

  • Macrophages are the "Swiss Army Knife" of Atherosclerosis: Their central role in plaque development, inflammation, and instability makes them a prime target for NPs. Their inherent phagocytic ability also makes them efficient "consumers" of NPs.
  • Multifunctionality is Key: The future of atherosclerosis treatment lies in NPs that can do more than one thing – simultaneously image plaque and deliver therapy, or target multiple pathological pathways within macrophages.
  • Repurposing is Powerful: Many NP strategies developed for cancer therapy show significant promise for atherosclerosis due to shared biological mechanisms, particularly the role of macrophages.
  • Targeting Specificity Matters: While passive NP uptake by macrophages is common, active targeting strategies (using specific ligands) can improve delivery efficiency and reduce off-target effects.
  • The "Theranostic" Advantage: Combining imaging and therapy in a single NP platform allows for real-time monitoring of treatment efficacy and personalized medicine approaches.

Key Results

The paper doesn't present single quantitative results but rather synthesizes findings from numerous preclinical studies. Key themes emerging from the reviewed literature include:

  • Improved Imaging: NPs incorporating fluorescent, MRI, or PET imaging agents have demonstrated the ability to visualize atherosclerotic plaques and macrophage accumulation in preclinical models.
  • Therapeutic Efficacy: Various NP designs have shown promise in reducing plaque inflammation, inhibiting macrophage proliferation, promoting cholesterol efflux, and restoring macrophage function in animal models.
  • Targeted Delivery: Studies highlight successful targeting of NPs to macrophages in atherosclerotic plaques, leading to enhanced therapeutic effects and reduced systemic toxicity compared to conventional drug delivery.
  • Clinical Translation Challenges: Despite promising preclinical results, the clinical translation of these NPs for CVD is slow, with only a few trials underway, indicating significant hurdles to overcome.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Clinical Translation Hurdles: The primary challenge is translating preclinical success to human patients. This includes issues with NP delivery to deep vascular tissues, potential off-target effects, and the need for rigorous safety and efficacy testing.
  • Nanotoxicity Concerns: The inherent toxicity of nanomaterials needs careful evaluation, especially regarding long-term effects and potential exacerbation of atherosclerosis through unintended inflammatory responses.
  • Scalability and Batch Variability: Producing NPs consistently and at scale for clinical use remains a significant engineering challenge.
  • Understanding the "Corona": The protein corona that forms on NPs in the bloodstream significantly influences their behavior, and a deeper understanding is needed for predictable outcomes.
  • Future Directions:
    • Developing NPs with improved targeting specificity to plaque macrophages, minimizing uptake by other tissue-resident macrophages.
  • Further exploration of NP repurposing from other disease areas.
  • Designing NPs that can overcome the limitations of current imaging techniques for early and accurate plaque detection.
  • Focusing on interdisciplinary collaboration between chemists, pharmacologists, physicists, and clinicians to accelerate translation.
  • Investigating the long-term safety and potential for unintended consequences of NP therapies.

Summary updated

Abstract

Despite the emergence of novel diagnostic, pharmacological, interventional, and prevention strategies, atherosclerotic cardiovascular disease remains a significant cause of morbidity and mortality. Nanoparticle (NP)-based platforms encompass diverse imaging, delivery, and pharmacological properties that provide novel opportunities for refining diagnostic and therapeutic interventions for atherosclerosis at the cellular and molecular levels. Macrophages play a critical role in atherosclerosis and therefore represent an important disease-related diagnostic and therapeutic target, especially given their inherent ability for passive and active NP uptake. In this review, we discuss an array of inorganic, carbon-based, and lipid-based NPs that provide magnetic, radiographic, and fluorescent imaging capabilities for a range of highly promising research and clinical applications in atherosclerosis. We discuss the design of NPs that target a range of macrophage-related functions such as lipoprotein oxidation, cholesterol efflux, vascular inflammation, and defective efferocytosis. We also provide examples of NP systems that were developed for other pathologies such as cancer and highlight their potential for repurposing in cardiovascular disease. Finally, we discuss the current state of play and the future of theranostic NPs. Whilst this is not without its challenges, the array of multifunctional capabilities that are possible in NP design ensures they will be part of the next frontier of exciting new therapies that simultaneously improve the accuracy of plaque diagnosis and more effectively reduce atherosclerosis with limited side effects.
BibTeX
@inproceedings{nankivell2024targeting,
  author = {Victoria Nankivell and Achini K. Vidanapathirana and Ayla Hoogendoorn and Joanne T. M. Tan and Johan Verjans and Peter J. Psaltis and Mark R. Hutchinson and Brant C. Gibson and Yiqing Lu and Ewa M. Goldys and Gang Zheng and Christina A. Bursill},
  title = {{Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease}},
  booktitle = {Cardiovascular},
  year = {2024},
  doi = {10.1093/cvr/cvae099},
}
Figure